Business Wire

Trend Micro Finds 72% of Remote Workers Have Gained Cybersecurity Awareness During Lockdown

1.7.2020 13:00:00 EEST | Business Wire | Press release

Share

Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global leader in cybersecurity solutions, today released survey results that show how remote workers address cybersecurity. Nearly three quarters (72%) of remote workers say they are more conscious of their organisation’s cybersecurity policies since lockdown began, but many are breaking the rules anyway due to limited understanding or resource constraints.

Trend Micro’s Head in the Clouds study is distilled from interviews with 13,200 remote workers across 27 countries on their attitudes towards corporate cybersecurity and IT policies. It reveals that there has never been a better time for companies to take advantage of heightened employee cybersecurity awareness. The survey reveals that the approach businesses take to training is critical to ensure secure practices are being followed.

The results indicate a high level of security awareness, with 85% of respondents claiming they take instructions from their IT team seriously, and 81% agree that cybersecurity within their organisation is partly their responsibility. Additionally, 64% acknowledge that using non-work applications on a corporate device is a security risk.

However, just because most people understand the risks does not mean they stick to the rules.

For example:

  • 56% of employees admit to using a non-work application on a corporate device, and 66% of them have actually uploaded corporate data to that application.
  • 80% of respondents confess to using their work laptop for personal browsing, and only 36% of them fully restrict the sites they visit.
  • 39% of respondents say they often or always access corporate data from a personal device – almost certainly breaking corporate security policy.
  • 8% of respondents admit to watching / accessing porn on their work laptop, and 7% access the dark web.

Productivity still wins out over protection for many users. A third of respondents (34%) agree that they do not give much thought to whether the apps they use are sanctioned by IT or not, as they just want the job done. Additionally, 29% think they can get away with using a non-work application, as the solutions provided by their company are ‘nonsense.’

Dr Linda K. Kaye, Cyberpsychology Academic at Edge Hill University explains: “There are a great number of individual differences across the workforce. This can include individual employee’s values, accountability within their organisation, as well as aspects of their personality, all of which are important factors which drive people’s behaviours. To develop more effective cybersecurity training and practices, more attention should be paid to these factors. This, in turn, can help organisations adopt more tailored or bespoke cybersecurity training with their employees, which may be more effective.”

“In today’s interconnected world, unashamedly ignoring cybersecurity guidance is no longer a viable option for employees,” said Bharat Mistry, Principal Security Strategist, Trend Micro. “It’s encouraging to see that so many take the advice from their corporate IT team seriously. Having said that, there are individuals who are either blissfully ignorant or worse still who think cybersecurity is not applicable them and will regularly flouter the rules. Hence having a one size fits all security awareness programme is a non-starter as diligent employees often end up being penalised. A tailored training programme designed to cater for employees may be more effective.”

The Head in the Clouds study looks into the psychology of people’s behaviour in terms of cybersecurity, including their attitudes towards risk. It presents several common information security “personas” with the aim of helping organisations tailor their cybersecurity strategy in the right way for the right employee.

About Trend Micro
Trend Micro Incorporated, a global leader in cybersecurity solutions, helps to make the world safe for exchanging digital information. Our innovative solutions for consumers, businesses, and governments provide layered security for data centers, cloud environments, networks, and endpoints. All our products work together to seamlessly share threat intelligence and provide a connected threat defense with centralized visibility and control, enabling better, faster protection. With more than 6,000 employees in over 50 countries and the world’s most advanced global threat intelligence, Trend Micro secures your connected world. For more information, visit www.trendmicro.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Funda Cizgenakad
media_relations@trendmicro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye